GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Pharmaceuticals Inc (NAS:CPRX) » Definitions » Price-to-Free-Cash-Flow

Catalyst Pharmaceuticals (Catalyst Pharmaceuticals) Price-to-Free-Cash-Flow : 28.42 (As of Apr. 28, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Catalyst Pharmaceuticals Price-to-Free-Cash-Flow?

As of today (2024-04-28), Catalyst Pharmaceuticals's share price is $14.89. Catalyst Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.52. Hence, Catalyst Pharmaceuticals's Price-to-Free-Cash-Flow Ratio for today is 28.42.

The historical rank and industry rank for Catalyst Pharmaceuticals's Price-to-Free-Cash-Flow or its related term are showing as below:

CPRX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.71   Med: 13.57   Max: 44.44
Current: 28.42

During the past 13 years, Catalyst Pharmaceuticals's highest Price-to-Free-Cash-Flow Ratio was 44.44. The lowest was 6.71. And the median was 13.57.

CPRX's Price-to-Free-Cash-Flow is ranked better than
51.4% of 214 companies
in the Biotechnology industry
Industry Median: 30.52 vs CPRX: 28.42

Catalyst Pharmaceuticals's Free Cash Flow per Share for the three months ended in Dec. 2023 was $0.47. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $0.52.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Catalyst Pharmaceuticals was -47.80% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 8.70% per year.

During the past 13 years, Catalyst Pharmaceuticals's highest 3-Year average Free Cash Flow per Share Growth Rate was 47.30% per year. The lowest was -104.70% per year. And the median was 1.95% per year.


Catalyst Pharmaceuticals Price-to-Free-Cash-Flow Historical Data

The historical data trend for Catalyst Pharmaceuticals's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalyst Pharmaceuticals Price-to-Free-Cash-Flow Chart

Catalyst Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.50 7.88 12.29 17.85 30.90

Catalyst Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.85 15.58 12.27 28.86 30.90

Competitive Comparison of Catalyst Pharmaceuticals's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Catalyst Pharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Catalyst Pharmaceuticals's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Catalyst Pharmaceuticals's Price-to-Free-Cash-Flow falls into.



Catalyst Pharmaceuticals Price-to-Free-Cash-Flow Calculation

Catalyst Pharmaceuticals's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=14.89/0.524
=28.42

Catalyst Pharmaceuticals's Share Price of today is $14.89.
Catalyst Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.52.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Catalyst Pharmaceuticals  (NAS:CPRX) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Catalyst Pharmaceuticals Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Catalyst Pharmaceuticals's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Catalyst Pharmaceuticals (Catalyst Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Executives
Molly Harper director 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
David S Tierney director C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Alicia Grande officer: Chief Accounting Officer 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Gary Ingenito officer: Chief Medical Officer 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Steve Miller officer: VP Development & Management 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Tamar Thompson director C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Patrick J Mcenany director, 10 percent owner, officer: President and Chief Executive C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Carmen Jeffrey Del officer: Chief Commercial Officer 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Brian Elsbernd officer: Chief Compliance/Legal Officer 355 ALHAMBRA CIRCLE, CORAL GABLES FL 33134
Philip H Coelho director C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Charles B O'keeffe director 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Donald A Denkhaus director 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Preethi Sundaram officer: Chief Product Devel. Officer 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Daniel Brennan officer: Chief Commercial Officer C/O INSYS THERAPEUTICS, INC, 1333 SOUTH SPECTRUM BLVD, SUITE 100, CHANDLER AZ 85286
M Douglas Winship officer: V.P. of Regulatory Operations 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134